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Feasibility of double-blind clinical trials with oral diacetylmorphine: A randomized 
controlled phase II study in an inpatient setting. 
Colom Farran J., Casas M., Pérez de los Cobos J., Del Río M., Roncero C., Castells X., Valero 
S., Eiroa-Orosa F.J., Batlle F., Trujols J. 
Running head: Feasibility of double-blind clinical trials with oral diacetylmorphine. 
Abstract 
The aim of this study was to evaluate the feasibility of conducting double blind controlled 
randomized clinical trials using twice a day immediate release oral diacetylmorphine (DAM) in 
heroin dependent patients, by means of measuring the capacity of oral DAM to block opiate 
withdrawal and clinicians’ ability to distinguish it from morphine and methadone.  
This was a randomized, phase II, double-blind, multicentre pilot study comparing immediate 
release oral DAM, slow-release oral morphine and oral methadone; administered twice a day 
during 10 days. Forty-five heroin-dependent patients were randomly assigned to these three 
treatment groups in an inpatient regime. 
Patients were stabilized with a mean of 350 (SD=193) mg of immediate release oral DAM, 108 
(SD=46.2) of slow release oral morphine and 40 (SD=17.9) mg of methadone. No statistically 
significant differences were found between any studied medication on clinical outcome. Neither 
patients nor clinicians were able to identify the administered medication. 
This study shows the feasibility of double blind clinical trials using b.i.d. immediate release oral 
DAM allowing further phase III clinical trials in the process of introducing oral DAM as a 
medication for heroin dependent patients not responding to standard maintenance treatments. 
Key words: Immediate release oral diacetylmorphine, slow-release oral morphine, methadone, 
double blind randomized clinical trial, feasibility studies, opiate dependence. 
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INTRODUCTION 
Heroin dependence is a devastating, chronic psychiatric disorder. The recent increase of opium 
production has resulted in an increase in heroin use in many Nations [1,2]. Between 12 and 21 
million people are opiate abusers [2]. Heroin is detected in 80% of acute drug-related deaths in 
the European Union, and almost half of treatment requests for illicit drug use were for heroin 
dependence [1]. Crude mortality rate and standardized mortality rate among opioid dependent 
users have been recently found to be, respectively, 2.09 per 100 person-years and 14.66, 
particularly during out-of-treatment periods [3]. 
Agonist maintenance treatment has become a treatment of choice for chronic opioid dependent 
patients [4] that cannot achieve abstinence. Methadone Maintenance Therapy (MMT) has shown 
to reduce heroin use [5-7], risk of HIV transmission [8], mortality [9] and crime [10,11]. Further, 
MMT is associated with global health [12], social functioning improvement [13], increased 
treatment retention [7,14] and reduction in criminality [15,16]. The use of MMT has been proven 
to be valid for a wide range of patients even irrespective of psychopathology [17]. 
However, MMTs have limited effectiveness for some patients [7,18,19] due to a variety of 
pharmacological individual and treatment factors. This has led to the development of alternative 
forms of maintenance treatments. At present, buprenorphine, a partial mu receptor agonist, 
although more expensive than methadone [20], has proven its effectiveness [21] and is currently 
being progressively introduced in both the United States and the European Union. 
Due to the limitations of methadone and buprenorphine, along with the increases in incidence of 
infectious diseases associated with heroin use (i.e. HIV, hepatitis B and C, and tuberculosis), 
various European countries have begun to consider alternative treatments [4], namely oral slow 
release morphine, [22-24] and parenteral diacetylmorphine (DAM) [25-27]. 
In the 1990´s, Swiss health authorities started several clinical trials studying DAM as a 
maintenance therapy for heroin-addicted patients who did not benefit from existing forms of 
Opioid Maintenance Therapy (OMT) [28]. Since then, clinical trials with intravenous or 
intrapulmonary DAM have been carried out in several countries (Switzerland, Netherlands, 
United Kingdom, Spain, Germany and Canada), showing DAM’s effectiveness as an alternative 
to conventional forms of maintenance treatment [29-34]. Presently, in the United Kingdom, 
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Switzerland, Netherlands, Germany and Denmark, DAM can be prescribed as a maintenance 
therapy in special cases, although, a recent publication shows its effectiveness for patients with 
no previous experience in maintenance treatments [35]. Nevertheless, in many western countries, 
parenteral DAM is rejected due to a wide range of factors: higher risk of overdose associated 
with this route of administration, residual “high” effect in some patients, higher costs of 
treatment than with MMT, social stigma, etc. Furthermore, because such trials conducted with 
intravenous DAM were not double blinded, the possibility of biased results cannot be ruled out. 
Finally, a high rate of adverse events related to the parenteral administration route were found, 
which can limit the implementation of large scale DAM maintenance programs [33]. 
In 1989, the Swiss authorities commissioned an expert report in which oral DAM was described 
as having clear prolonged opiate effects without the intense and immediate “high” effect reported 
with intravenous DAM [36]. As a result of this expert report, oral DAM has been tried in 
observational studies in Switzerland that showed high retention compared to historical controls. 
Furthermore, oral DAM was well tolerated and the rates of serious adverse events were low [37]. 
Oral DAM has been shown to provide a suitable pharmacokinetic profile for its clinical use in 
heroin-dependent patients [38], and clinical trials are being prepared in Andalusia (Spain) and 
Vancouver (Canada). Since oral DAM does not produce an intense and immediate “high” effect 
and has a suitable pharmacokinetic profile, such oral formulation could be considered as an 
alternative to intravenous or intrapulmonary DAM. 
Our group planned to conduct a pivotal clinical trial with oral DAM avoiding the risk related to 
intravenous or inhalant administration. Before a phase III study in an outpatient setting using 
objective outcome measures could be conducted, the Health Authorities required the conduction 
of a randomized, double-blind, phase II clinical trial involving a small number of participants, in 
order to generate initial data on its ability to decrease opioid withdrawal with a twice a day 
(b.i.d) schedule and to determine whether patients and staff could identify the administered 
substance that would prevent effective blinding. This will be done by means of measuring the 
capacity of oral DAM to block opiate withdrawal and clinicians’ ability to distinguish it from 
morphine and methadone. The present pilot study compared immediate release oral DAM, slow 
release oral morphine and methadone in a b.i.d. regime, in order to study the feasibility of 
Página 5 de 18 
 
running double-blind clinical trials with oral DAM, allowing future phase III clinical trials, 
following the standard clinical research procedures for the development of new medications. 
METHOD 
Participants 
Forty-five heroin-dependent patients, aged 18 to 55, were enrolled in this pilot study between 
2004 and 2006. Potential participants were selected from individuals not currently receiving 
treatment but seeking for heroin-dependence treatment. Patients were referred from various 
outpatient substance abuse clinics in Catalonia, Spain. Participants had to meet criteria for heroin 
dependence according to DSM-IV-TR [39] and have undergone at least one episode of MMT 
lasting at least one month during which they received a minimum dose of 60 mg per day. 
Participants also had to test negative for methadone by urinalysis at the screening visit. Subjects 
were excluded if they were alcohol, cocaine or benzodiazepine dependent, had a major 
psychiatric or medical disorder, or were receiving treatment with other drugs that could interact 
with methadone. Women were excluded if they were pregnant, breast-feeding, or were unwilling 
to use effective contraception methods. Informed consent was obtained from all participants 
prior to their participation in the study. Participants received no payment for participation. This 
clinical trial was approved by the internal review boards of the participating hospitals and the 
Spanish Drug Regulatory Agency and was conducted in accordance with the Declaration of 
Helsinki and subsequent amendments. 
Design 
A randomized, double-blind, multicentre pilot study was carried out at the Drug Addiction Units 
of the Departments of Psychiatry of three General Hospitals in Catalonia, Spain. Forty-five 
participants were randomly assigned to three treatment groups (immediate release oral DAM, 
slow release oral morphine, or methadone), with 15 participants per group (see figure 1). 
Participants were admitted to the Drug Addiction Units and received study medication for 10 
days. Randomization was performed by a research pharmacist who had no contact with 
participants or study physicians, using a random numbers table, stratified by centre. Thus, each 
centre included five patients in each study group. Allocation was concealed by using sequentially 
numbered, opaque, sealed envelopes.  
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The main study variables were: 1) mean dose administered to block opioid withdrawal 
syndrome, 2) presence of subjective and objective opiate withdrawal symptoms, and 3) patient 
and staff beliefs of which type of opioid was administered. In addition, study retention, heroin 
craving, symptoms of depression and anxiety, physician and patient’s Clinical Global Impression 
were determined. Opiate withdrawal symptoms were assessed using the Subjective Opiate 
Withdrawal Scale and the Objective Opiate Withdrawal Scale [40], craving with a 10 cm Visual 
Analogue Scale [41], global improvement with the Clinical Global Impression Scale, [42], 
depressive symptoms by the Beck Depression Inventory[43], anxiety symptoms by the State-
Trait Anxiety Inventory [44] and severity of addiction with the Addiction Severity Index [45]. 
All variables were assessed daily. Patients’ and staffs' beliefs regarding the type of opiate 
administered were requested on the last day of treatment. 
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Interventions 
The study was conducted in an in-hospital setting. Study medication consisted of immediate 
release oral DAM, slow release oral morphine and methadone, for which, minimum available 
dosage oral presentations were 50 mg, 15 mg and 5 mg, respectively. Slow release oral DAM 
was not used because when the study was conducted, the pharmacokinetic studies of this 
sustained release formulation were not available. 
Patients were stabilized with an oral b.i.d. flexible dose regime using standard dose increments 
of 50 mg, 15 mg and 5 mg of immediate release DAM, slow release morphine and methadone 
respectively All opioids were re-encapsulated with an identical protective coating for each dose 
(tree different colors for each different dose). The protocol of drug administration was as 
follows: During the first day, patients were monitored and each time they showed objective signs 
of opiate withdrawal as measured by the Opiate Withdrawal Scale (OWS), one standard dose 
was given. The total amount of medication administered during the first day was divided into 
two equal doses given in a 12 hours interval on the second day. If the sum of the number of 
standard doses administered on the first day was an odd number, the amount of medication 
needed could not be divided into two equal doses. In this case, the doses were administered in 
such a way that the morning dose was higher than the afternoon one while maintaining the same 
total dosage per day. During this second day, rescue standard doses could be administered if a 
patient showed objective signs of opiate withdrawal according to the OWS. The total amount of 
medication administered (scheduled and rescues) during the second day was subjected to the 
same procedure to calculate the doses for the third day. The same procedure was used during the 
remaining days of the trial. Once the trial ended, all study medication was stopped and patients 
could choose between opioid detoxification and MMT. All participants received no standardized 
psychosocial management.  
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Statistical analysis 
Statistical analysis was performed by intention to treat. The study examined differences within 
each group of treatment comparing the changes in scores at baseline and at 10 days. The 
difference between baseline and final values was used to carry out the analysis of treatment 
efficacyand Cohens’ d of these differences were calculated with 95% confidence intervals. Last 
observation carried forward methodology was used for imputing missing values.  
Sociodemographic data was analysed using chi squared or mean comparisons according the 
nature of variables. Analysis of variance (ANOVA) was used to test differences between the 
three treatment groups on differences between baseline and last moment. Hypotheses were two-
tailed and 95% confidence level was used. 
RESULTS 
As shown in Table 1, the sample was composed of 84.4% men and mean age was 34.7 (SD=5.1). 
93.3% had at least primary studies and 44.7% were employed. The most common route of heroin 
use was intravenously (71.4%), followed by intrapulmonary (21.4%) and intranasally (7.1%). 
Most patients (71.1%) had failed previously one MMT episode and the remaining 28.9% had 
failed two or more. Nicotine dependence was present in 85.4% of the sample, HIV infection in 
15.6% and HCV infection in 75.6%. No statistically significant differences were found between 
treatment groups in baseline characteristics. No statistically significant differences in ASI scores 
were observed between the study groups at baseline. 
Table 1: Baseline characteristics of randomized patients. 
 
 Heroin 
(n=15) 
Morphine 
(n=15) 
Methadone 
(n=15) 
Gender (% men) 100 73.3 80.0 
Age (mean±SD) 35.5±5.0 34.7±4.2 33.9±6.4 
At least basic studies completed (%) 53.3 73.3 73.4 
Unemployed (%) 60 60 40 
Number of days of heroin consumption during last month 
(mean±SD) 
29.5±1.5 28.3±4.8 30±.0 
Number of previous maintenance treatments (mean±SD) 1.9±1.2 1.4±.8 1.3±.8 
Nicotine dependence (%) 85.7 78.6 92.3 
Baseline cocaine positive (%) 60.0 71.4 60.0 
HIV (%) .0 26.7 20 
HCV (%) 66.7 80 80 
Página 9 de 18 
 
 Heroin 
(n=15) 
Morphine 
(n=15) 
Methadone 
(n=15) 
Route of heroin consumption    
Intravenous (%) 71.4 69.2 73.3 
Intrapulmonary (%) 14.3 30.8 20.0 
Intranasal (%) 14.3 .0 6.7 
Addiction Severity Index Composite Scores at baseline 
(mean±SD) 
(n=10) (n=5) (n=10) 
Physical state of health .48±.33 .26±.36 .35±.29 
Economic situation .7±.37 .72±.22 .56±.24 
Drug use .38±.1 .44±.14 .42±.12 
Alcohol use .6±.1 .8±.13 .18±.17 
Legal status and problems .39±.32 .18±.15 .22±.27 
Family relationships .49±.32 .37±.14 .47±.22 
Mental status .31±.21 .33±.21 .39±.28 
* No statistically significant differences were found. 
 
Patients were stabilized with a mean of 350 (SD=193) mg of oral immediate release heroin, 108 
(SD=46.2) of oral slow release morphine and 40 (SD=17.9) mg of methadone. A table showing 
the dose of study medication that was administered every study day can be found as a web-
appendix (Table 1-online). The majority of patients (82.2%) completed the study. No group 
effect was found regarding retention in treatment. However, as it was the principal study 
outcome it was further explored. Accordingly, in the context of post-hoc comparisons, morphine 
treatment was found to be statistically lower than heroin and methadone (z=2.12, p=.034). 
Nevertheless this effect disappeared after Bonferroni adjustment for multiple comparisons 
(.05/3=.017). Treatment improved the scores in all areas (withdrawal symptoms, craving, mood, 
anxiety and clinical impression) assessed for each group separately from baseline to study end 
(Table 2). Nevertheless, no statistical differences were found in any of these measures between 
the three different treatments groups. 
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Table 2: Efficacy of oral presentations of IR heroin, SR morphine and methadone. 
 
Heroin 
(n=15) 
Morphine 
(n=15) 
Methadone 
(n=15) 
Completers 14 10 14 
Retention (%) 93.3 66.7 93.3 
Dose (in SU) 7  3.9 7.2  3.1 8  3.6 
Dose (in mg) 350  193 108  46.2 40  17.9 
Rescues (in SU) -.16  0.29 -.25  0.61 .03  .30 
Rescues (in mg) 8  14.5 3.8  9.15 .15  1.50 
Withdrawal syndrome    
Baseline OOWS 4.07  2.69 5.14  3.21 5.47  3.80 
1 OOWS -3.1  2.5 (d=1.15; CI95% 0.38 – 1.92) 
-3.6  2.9 (d=1.12; CI95% 0.35 – 
1.89) 
-4.5  4.6 (d=1.18; CI95% 0.40 – 
1.96) 
SOWS basal 19.00  11.39 25.14  12.49 23.13  14.99 
 SOWS -14.8  13.5 (d=1.30; CI95% 0.51 – 2.09) 
-11.1  10.5 (d=0.89; CI95% 0.14 – 
1.64) 
- 19.9  16.0 (d=1.33; CI95% 0.54 
– 2.12) 
Craving (VAS)    
Baseline craving 4.14  3.86 5.34  3.93 5.56  3.70 
 Craving -2.3  4.6 (d=0.60; CI95% 0 – 1.33) -3.1  3.4 (d=0.79; CI95% 0.05 – 1.53) 
-4.8  4.4 (d=1.30; CI95% 0.51 – 
2.09) 
Depressive symptoms    
Baseline BDI 16.71  6.06 20.29  7.49 19.47  12.91 
 BDI -8.43  6.90 (d=1.40; CI95% 0.60 – 2.20) 
-6.43  8.34 (d=0.86; CI95% 0.11 – 
1.61) 
-9.47  7.32 (d=0.77; CI95% 0.03 – 
1.51) 
%  BDI  50% 66.7 46.7 86.7 
Anxiety symptoms    
STAI basal 30.07  9.21 36.43  7.68 34.93  9.32 
 STAI -10.00  10.38 (d=1.09; CI95% 0.32 – 1.86) 
-12.50  11.13 (d=1.63; CI95% 0.80 
– 2.46) 
-13.57  7.29 (d=1.46; CI95% 0.65 
– 2.27) 
%  STAI  30% 53.3 46.7 66.7 
Observer rated baseline 
impression 2.53  1.06 2.93  1.33 2.47  1.06 
 impression -1.00  1.22 (d=0.94; CI95% 0.19 – 1.69) 
-0.70  1.16 (d=0.53; CI95% 0 – 
1.26) 
-1.08  1.26 (d=1.02; CI95% 0.26 – 
1.78) 
Patient rated baseline 
impression 2.47  1.25 2.93  1.33 2.36  1.15 
 impression -1.54  1.71 (d=1.23; CI95% 0.45 – 2.01) 
-0.70  1.16 (d=0.53; CI95% 0 – 
1.26) 
-1.08  1.26 (d=1.11; CI95% 0.34 – 
1.88) 
* No statistically significant differences were found. 
NA: not assessed, SU: standard unit 
1 : Difference between basal to final score.  
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Blinding was good as proved by the fact that the sum of correct judgements about the 
administered opioid was 49% for physicians and 29% for patients. No statistically significant 
differences were found between proportions of concordance in the two groups. Neither clinicians 
nor patients reported a statistically different rate of correct judgements than expected from 
chance. 
Regarding safety, 20 different types of adverse events (AEs) were reported during the 10-day 
study period (Table 3). Only one AE (comitial crisis in a patient with history of seizures) was 
considered serious, and entailed the withdrawal of the patient from the study. Finally, no 
significant differences were found in the number of AEs between study groups. 
Table 3: Adverse events (AEs) reported during the 10-day study period. 
  
 
Heroin 
(n=15) 
Morphine 
(n=15) 
Methadone 
(n=15) 
 Withdrawal due to SAE 0 1 (6.7%) 0 
 Reported SAEs:    
 Insomnia 7 (46.7%) 9 (60%) 11 (73.3%) 
 Vomits 0 0 2 (13.3%) 
 Ototubaritis 0 1 (6.7%) 0 
 Arterial Hypotension 0 1 (6.7%) 1 (6.7%) 
 Constipation 4 (26.7%) 2 (13.3%) 4 (26.7%) 
 Cephalea 1 (6.7%) 1 (6.7%) 0 
 Chalazion 1 (6.7%) 0 0 
 Phlebitis 0 2 (13.3%) 0 
 Pruritus 2 (13.3%) 1 (6.7%) 2 (13.3%) 
 Dizziness 0 0 1 (6.7%) 
 Epigastralgia/dyspepsia 2 (13.3%) 0 3 (20%) 
 Odontalgia 0 0 1 (6.7%) 
 Posttraumatic pain 0 0 2 (13.3%) 
 Heart block 0 0 1 (6.7%) 
 Backalgia  0 0 1 (6.7%) 
 IVRS 0 0 1 (6.7%) 
 Conjunctivitis 0 1 (6.7%) 0 
 Pneumonia  1 (6.7%) 0 0 
 Diarrhea 0 0 1 (6.7%) 
 Convulsions 0 1 (6.7%) 0 
 
DISCUSSION 
This first phase II study requested by the Health Authorities constitutes the first randomized 
clinical trial comparing b.i.d. immediate release oral DAM, slow release oral morphine and 
methadone supporting the feasibility of running double blind clinical trials with oral DAM in 
opioid dependent patients. This is supported by first, the finding that the administration of 
immediate release oral DAM could effectively reduce the opioid withdrawal syndrome, decrease 
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heroin craving and improve depressive and anxiety symptoms similarly as slow release oral 
morphine and methadone. And second, because neither patients nor clinicians seem to be able to 
identify which was the administered drug. 
The dose needed to block opiate withdrawal with immediate release oral DAM, slow release oral 
morphine and methadone was 350 mg/d, 108 mg/d and 40 mg/d, respectively. The oral DAM to 
methadone ratio in our study was approximately of 9, which is quite similar to the 
bioequivalence found from the Swiss heroin-assisted treatment studies [37,46]. Regarding 
morphine stabilization dose, it was expected to be higher because morphine bioavailability 
appears to be higher with oral DAM than with oral morphine [47]. Other studies have found that 
SR morphine to methadone is 4.5 [48] while in our study it was of 2.7. It is likely that SR 
morphine dose in our study was too low, thereby explaining the lower retention in treatment 
amongst patients randomized to SR morphine compared to methadone or DAM. Given this 
limitation, the bioequivalence between oral methadone and oral DAM must be seen as more 
convincing than those between methadone and morphine. 
It is notable that patients were stabilized with a b.i.d. schedule of the three study medications. 
This finding, striking for oral DAM, is consistent with that of recent studies showing that heroin 
dependent patients are able to be maintained with an average of 2 intrapulmonary or intravenous 
DAM administrations [30,33]. It can be explained because, as shown in pharmacokinetic studies 
[38,49], DAM metabolization yields the production of active metabolites including 6-mono-
acetyl-morphine, morphine, and morphine-6-glucoronide with long half-life. The existence of 
these metabolites could explain why oral and parenteral DAM are able to block opiate 
withdrawal syndrome with a b.i.d. administration, which is a suitable regime for a maintenance 
treatment. As slow release oral DAM is been developed at present [50], it is possible to consider 
that in a near future could be reliable to stabilize heroin addicts with a once a day regime of slow 
release oral DAM. 
Patients were stabilized with 40 mg of methadone. It must be noted that patients were admitted 
to a detoxification unit and in this setting it is likely that the exposure to cues is lower thereby 
decreasing craving, anxiety and withdrawal symptoms and the need for methadone. Besides, it 
must also be stressed that this dose is lower than the one used in methadone maintenance 
programs for which doses above 60 mg/day are recommended. Higher doses are needed in 
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methadone maintenance programs because their aim is not only to prevent heroin withdrawal but 
also to cause a narcotic blockade [51]. Given that our study has shown that the equivalent dose to 
treat the opioid withdrawal syndrome with oral DAM and methadone was 350 mg/d and 40 
mg/d, respectively, and considering that in methadone maintenance programs patients are 
stabilized with doses ranging 60-125 mg/d, we reckon that the dose of oral DAM needed in 
maintenance programs will be between 540 mg/d and 1100 mg/d.  
This study also shows that oral DAM has a good safety profile. No serious physical complaints 
were reported and although high tolerance has been documented for DAM, this study shows that 
when is administered under controlled clinical conditions, even in a flexible regime, has low risk 
of physical tolerance. Finally no overdoses were registered. In intravenous DAM studies, 
overdose was the most the hazardous adverse event; nevertheless, it mostly occurred in heroin 
administration clinics and were treated and resolved without sequelae or hospital admission [33]. 
Some study limitations must be stressed. The sample size was small and, as a consequence, the 
power of statistical results was also low. In this study inferential statistics have only an 
exploratory purpose. However, despite of the large confidence intervals observed, also 
consequence of the sample size, some effects size effect size obtained comparing basal and final 
data can be interpreted as large [52]. Under our point of view, it is important to remark that 
although some percentual differences between groups should be perceived as clinically relevant 
(for example different retention percentages). A placebo arm was not included in order to 
provide an active treatment to all study participants according to the European regulation. 
Patients were treated in an inpatient regime in the context of a short follow-up, with reduced 
exposition to environmental stimulus that may lead to drug craving. This artificial setting was 
needed to monitor patient safety and warrant double blind conditions. Another issue that limits 
the external validity of our study is that we excluded patients with comorbid benzodiazepine, 
cocaine or alcohol dependence, which are rather prevalent amongst heroin dependent patients. 
Besides, our study focussed on clinical outcome measures but we did not fully investigate the 
behavioural effects of oral DAM neither its impact over physiological variables, which should be 
studied in the future to characterize the clinical pharmacology of this drug. Although 
administering twice a day methadone limits the external validity of our study, dividing 
methadone dose is usually recommended in patients that can be very fast methadone 
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metabolizers or in patients for which once a day methadone administration cannot prevent heroin 
craving for 24 hours [53,54]. Furthermore, using once a day oral DAM was not possible given 
that, by the time this study was designed and approved, the slow release formulation had not 
completed the phase I studies [50]. Therefore, a twice a day administration of all study 
medication was needed to allow double-blind conditions. Given that slow release DAM 
formulation is available nowadays, caution is recommended when extrapolating our findings to 
this formulation. The present study was not aimed either at investigating oral DAM efficacy in 
respect to morphine and methadone, or in proposing it as a maintenance treatment but at looking 
the feasibility of double-blind clinical trials with oral DAM. Our findings suggest that 
[28,30,32,33]the oral formulation of DAM could be effective and safe, allowing double blind 
clinical trials in future research with DAM as a maintenance treatment in outpatient resources.  
Further research is warranted using double blind, randomized clinical trials with oral DAM in the 
process of introducing oral DAM as a medication in heroin addiction. 
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